english.prescrire.org

Welcome to the Prescrire in English website

Reliable, rigorously independent information on treatments and healthcare strategies,
to enable fully informed decision-making. Prescrire is financed by its subscribers.
No grants, no advertising. No shareholders, no sponsors.

In Prescrire's Spotlight

Statins in primary cardiovascular prevention. Little benefit, documented harms and many uncertainties regarding long-term use

1 July 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
In the July/August issue of Prescrire International: pembrolizumab (Keytruda°) in Hodgkin lymphoma with no further treatment options

1 July 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Prescrire's review of drug packaging in 2017: some progress, but many risks remain

1 July 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Multiple sclerosis: a drug that should never have been authorised

1 July 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Drugs for Alzheimer's disease: finally delisted in France!

15 June 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Drug prices, therapeutic value and access to medicines: civil society adds its voice to the debate in France, to defend the public interest

20 June 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Wholly self-financed through subscriptions, Prescrire makes its accounts public every year

1 June 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
"Preventing Overdiagnosis 2018": an international conference in Copenhagen, 20-22 August 2018

1 May 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
"Top Texts of 2017", from the Editors of Prescrire International

1 December 2017

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Receive the free, monthly "Independent Drug & Healthcare Newsletter"

1 September 2017

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Subscribe online for full access to content from Prescrire International

1 September 2017